CG Oncology, Inc. (CGON)
54.92
-1.75
(-3.09%)
USD |
NASDAQ |
Jun 10, 16:00
55.21
+0.29
(+0.53%)
Pre-Market: 08:22
CG Oncology Enterprise Value : 3.765B for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 3.765B |
| June 09, 2026 | 3.919B |
| June 08, 2026 | 3.719B |
| June 05, 2026 | 3.659B |
| June 04, 2026 | 3.868B |
| June 03, 2026 | 3.721B |
| June 02, 2026 | 3.818B |
| June 01, 2026 | 4.144B |
| May 29, 2026 | 4.413B |
| May 28, 2026 | 4.276B |
| May 27, 2026 | 3.955B |
| May 26, 2026 | 4.045B |
| May 22, 2026 | 4.240B |
| May 21, 2026 | 4.268B |
| May 20, 2026 | 4.282B |
| May 19, 2026 | 4.161B |
| May 18, 2026 | 4.131B |
| May 15, 2026 | 4.461B |
| May 14, 2026 | 4.677B |
| May 13, 2026 | 5.046B |
| May 12, 2026 | 4.886B |
| May 11, 2026 | 4.659B |
| May 08, 2026 | 4.684B |
| May 07, 2026 | 4.647B |
| May 06, 2026 | 4.551B |
| Date | Value |
|---|---|
| May 05, 2026 | 4.482B |
| May 04, 2026 | 4.525B |
| May 01, 2026 | 4.407B |
| April 30, 2026 | 4.446B |
| April 29, 2026 | 4.281B |
| April 28, 2026 | 4.347B |
| April 27, 2026 | 4.452B |
| April 24, 2026 | 4.606B |
| April 23, 2026 | 4.706B |
| April 22, 2026 | 4.705B |
| April 21, 2026 | 4.867B |
| April 20, 2026 | 4.748B |
| April 17, 2026 | 4.998B |
| April 16, 2026 | 4.413B |
| April 15, 2026 | 4.523B |
| April 14, 2026 | 4.490B |
| April 13, 2026 | 4.525B |
| April 10, 2026 | 4.525B |
| April 09, 2026 | 4.596B |
| April 08, 2026 | 4.622B |
| April 07, 2026 | 4.699B |
| April 06, 2026 | 4.513B |
| April 02, 2026 | 4.507B |
| April 01, 2026 | 4.450B |
| March 31, 2026 | 4.523B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cogent Biosciences, Inc. | 4.797B |
| Vera Therapeutics, Inc. | 1.746B |
| Arrowhead Pharmaceuticals, Inc. | 9.517B |
| Oncolytics Biotech, Inc. | 87.93M |
| Sangamo Therapeutics, Inc. | 53.47M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -60.20M |
| Revenue (Quarterly) | 1.083M |
| Total Expenses (Quarterly) | 61.28M |
| EPS Diluted (Quarterly) | -0.7123 |
| Gross Profit Margin (Quarterly) | -177.3% |
| Profit Margin (Quarterly) | -5.56K% |
| Earnings Yield | -4.27% |
| Normalized Earnings Yield | -4.265 |